Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November CrashThe Motley Fool • 02/17/26
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue EstimatesZacks Investment Research • 02/12/26
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 02/12/26
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/05/26
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ETGlobeNewsWire • 01/26/26
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio GrowthGlobeNewsWire • 01/12/26
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026GlobeNewsWire • 01/05/26
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?Zacks Investment Research • 12/26/25
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia TranscriptSeeking Alpha • 12/24/25
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in LabelZacks Investment Research • 12/24/25
U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-ThalassemiaGlobeNewsWire • 12/24/25
Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due DateZacks Investment Research • 12/09/25
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study ResultsZacks Investment Research • 11/20/25
Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease TranscriptSeeking Alpha • 11/19/25